New drug hopes to stop bleeding in rare blood disorder

NCT ID NCT07273721

Recruiting now Disease control Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 20, 2026 · Updated 22 times

Summary

This study tests a new drug called BT200 in 4-6 adults with type 2B von Willebrand disease who have low platelets and a history of bleeding. The drug aims to raise levels of a key clotting protein and platelets, which should reduce bleeding episodes. Participants receive both BT200 and a placebo at different times to compare effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD), TYPE 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Medical University of Vienna, Department of Clinical Pharmacology
RECRUITING

Vienna, State of Vienna, 1090, Austria

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact

Contact

Contact

Contact

Contact

Contact

Contact

Conditions

Explore the condition pages connected to this study.

VON WILLEBRAND DISEASE (VWD), TYPE 2 VON WILLEBRAND DISEASE (VWD), TYPE 2